<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363934</url>
  </required_header>
  <id_info>
    <org_study_id>GC1113_P1</org_study_id>
    <nct_id>NCT01363934</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin</brief_title>
  <official_title>A Dose-Block Randomized, Double-blind Placebo Controlled, Open-label Active Controlled, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GC1113 After Single Intravenous/Subcutaneous Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symyoo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Dose-Block Randomized, Double-blind Placebo controlled, Open-label Active
      controlled, Dose-escalation Study to investigate the safety, tolerability, and
      Pharmacokinetics/Pharmacodynamics of GC1113 after Single Intravenous/Subcutaneous
      Administration in Healthy Male Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/ Tolerability Evaluation</measure>
    <time_frame>Up to 29 days after investigational product administration</time_frame>
    <description>Number of subjects with Adverse events, Physical examinations, Vital signs, electrocardiogram (ECG), Laboratory tests (including hematology, chemistry, coagulation, urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast of GC1113, Cmax of GC1113</measure>
    <time_frame>Up to 29 days after investigational product administration</time_frame>
    <description>Blood test, urinalysis, hemoglobin, reticulocyte count, reticulocyte hemoglobin contents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of GC1113</measure>
    <time_frame>Up to 29 days after investigational product administration</time_frame>
    <description>Antibody (GC1113) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare safety and Pharmacokinetics/Pharmacodynamics with active control</measure>
    <time_frame>Up to 29 days after investigational product administration</time_frame>
    <description>Abdominal Ultrasonograpy, egio genus radiology, blood test, urinalysis, hemoglobin, reticulocyte count, reticulocyte hemoglobin contents</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin alfa 30ug/kg by IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darbepoetin alfa 30ug/kg once intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin alfa 30ug/kg by SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darbepoetin alfa 30ug/kg once subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC1113</intervention_name>
    <description>Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.
Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.</description>
    <arm_group_label>Darbepoetin alfa 30ug/kg by IV</arm_group_label>
    <arm_group_label>Darbepoetin alfa 30ug/kg by SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Adult male subjects between 20 to 55 years of age

          -  60kg ≤ weight ≤ 90kg, 19 ≤ BMI ≤ 27

          -  12 g/dL ≤ Hemoglobin ≤ 16 g/dL within the 28 days prior to investigational product
             (IP)injection

          -  WBC ≥ 3.0Ⅹ10^9/L, platelet ≥ 140Ⅹ10^9/L within the 28 days prior to IP injection

        Exclusion Criteria:

          -  Allergic to IP ingredients

          -  History of uncontrolled liver, kidney, respiratory, endocrine, neurology, immunology,
             hematology, mental symptom, circulatory and malignancy disease

          -  Prior exposure to EPO, darbepoetin, other EPO, immunoglobulin, IV iron supplementation

          -  History of hypersensitivity reaction to EPO, darbepoetin, excipient of IP or
             hyperergia to iron supplementation

          -  Epilepsy within the 6 months prior to IP injection

          -  Positivity for HIV antibody, HBsAg, HCV antibody test

          -  Spleen length &gt; 16㎝
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>EPO-hFC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

